A message from Stephen and John
It was also an aspiration that we knew could lead to a profound impact on human well-being enabled by the delivery of precision products that protect the sample integrity and minimise result variation, leading to more informed decisions and treatments.
We welcome you as an investor and invite you to take a tour of the Trajan facilities around the world to meet some of our incredible team who, like us, are supporting science that benefits people

Solutions to support pharmaceutical applications at all stages
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore
veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam
voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur
magni dolores eos qui ratione.
Goal: Give an overview in why you should invest with Trajan. Highlight key reasons to
invest in Trajan by showcasing the company’s performance, growth, and strategic
initiatives, demonstrating its potential for long-term value.
Audience value: Provides investors with a clear understanding of the benefits and
opportunities that come with investing in Trajan, emphasising financial growth,
innovation, and the company's positive impact on the scientific and medical fields.






Latest news and events
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua.
Goal: Present the latest investor news and events to keep stakeholders informed
about Trajan’s updates, achievements, and industry participation.
Audience value: Audiences will view Trajan as a transparent and informative
company, staying current with industry news and developments, which strengthens
trust and engagement with investors.
Antipodean Analytical Adventure
New products launch at Pittcon 2015
The medical technology industry to gather at AusMedtech
Latest announcements and reports
Loading reports...
Financial Scorecard
FY 2025
FINANCIAL RESULTS
|
Group Revenue |
$166.5M |
UP 7.4% (PCP $155.0M) |
|
nEBITDA |
$15.5M |
UP 26.2% (PCP $12.3M) |
|
Proforma Gross Margin |
39.8% |
DOWN 1.3 POINTS (PCP 41.1%) |
COMPONENTS & CONSUMABLES: |
Includes parts, supplies, components, and consumable products across the Group. |
|
|---|---|---|
| Revenue |
$102.7M |
(PCP $96.2M) |
| nEBITDA |
$34.9M |
(PCP $32.3M) |
| Proforma Gross Margin |
41.6% |
(PCP 41.1%) |
CAPITAL EQUIPMENT: |
Includes robotic workflow automation systems, online and laboratory instruments, and parts and services related to them. |
|
|---|---|---|
| Revenue |
$58.6M |
(PCP $53.9M) |
| nEBITDA |
$9.7M |
(PCP $9.7M) |
| Proforma Gross Margin |
35.1% |
(PCP 40.2%) |
DISRUPTIVE TECHNOLOGIES:
|
Includes products and services related to micro-sampling, devices, services, and other related investments as well as miniaturised, portable instrumentation, i.e. Versiti. |
|
|---|---|---|
| Revenue |
$5.1M |
(PCP $4.9M) |
| nEBITDA |
($1.5M) |
(PCP $(4.9M)) |
| Proforma Gross Margin |
57.0% |
(PCP 52.7%) |
Investor Contact
Sign up for email alerts
Stay updated with ASX announcements and quarterly newsletters




